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Abstract
Background: Mycobacterium avium subspecies paratuberculosis (MAP) is suspected to be a causative agent in
human Crohn’s disease (CD). Recent evidence suggests that pathogenic mycobacteria and MAP can induce the
expression of Matrix Metalloproteinases (MMP), which are the main proteases in the pathogenesis of mucosal
ulcerations in inflammatory bowel disease (IBD). Within this study we assessed the prevalence of intestinal MAP
specific DNA in patients with Crohn’s disease, ulcerative colitis (UC), and healthy controls. We further analysed
regulation patterns of MMPs in mucosal tissues of UC patients with and without intestinal MAP DNA detection.
Methods: Colonic biopsy samples were obtained from 63 Norwegian and German IBD patients and 21 healthy
controls. RNA was quantified by quantitative real-time polymerase chain reaction (PCR) to study MMP gene
expression in both pathological and healthy mucosal specimens. The presence of MAP DNA in colonic mucosa
was examined using MAP specific PCR.
Results: MAP DNA was detected in 20% of UC patients and 33% of healthy controls but only in 7% of patients
with CD. UC patients treated with corticosteroids exhibited a significantly increased frequency of intestinal MAP
DNA compared to those not receiving corticosteroids. Expression of MMP-1, -2, -7, -9, -13, -19, -28 and TNF-a did
not differ between UC patients with presence of intestinal MAP DNA compared to those without. MMP-2, MMP-9
and MMP-13 were significantly decreased in UC patients receiving corticosteroids.
Conclusions: The presence of intestinal MAP specific DNA is not associated with altered MMP expression in UC
in vivo. Corticosteroids are associated with increased detection of intestinal MAP DNA and decreased expression
of certain MMPs. Frequent detection of MAP DNA in healthy controls might be attributable to the wide
environmental distribution of MAP and its presence in the food-chain.
Background
Mycobacterium avium strains are widely distributed in the
environment and inhabit animal and human intestines.
Mycobacterium avium subsp. paratuberculosis (MAP) is
the causative agent of Johne’s disease, a chronic granulo-
matous inflammation of the intestines in ruminants like
dairy cows and many other species, including primates [1].
Crohn’s disease (CD) and ulcerative colitis (UC) repre-
sent the major forms of human idiopathic inflammatory
bowel disease (IBD). Accumulating evidence suggests
that CD results from an excessive mucosal immune
response towards intestinal microbes in a genetically
susceptible host [2]. Since the initial description of
clinical similarities between Crohn’s disease and Johne’s
disease in cattle in 1913 [3], it has been hypothesized
that MAP might represent a causative agent in CD.
Since then, a number of studies and meta-analyses have
reported about a more frequent detection of MAP in
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patients with CD than in controls [4-7]. Nevertheless, it
is still a matter of controversy whether MAP represents
an etiologic factor for CD or rather a secondary invader
of inflamed intestinal mucosa [6,8,9]. So far, in vitro stu-
dies have identified increased TNF-a levels in mucosal
organ culture supernatants from MAP positive CD
patients as well as an increased T-cell proliferation upon
incubation of peripheral blood mononuclear cells from
CD patients with MAP as pathogenic mechanisms and
cellular responses [10,11].
Matrix Metalloproteinases (MMPs) are a family of
Zn2+-dependent endopeptidases that are considered to
be the most potent proteases in the turnover of the
extracellular matrix (ECM) [12]. In addition to their
capability of degrading virtually all protein components
of the ECM, MMPs regulate a variety of non-matrix
substrates such as chemokines, cytokines and growth
factors and influence the function and migration of
inflammatory cells [12]. They are considered to be the
predominant proteases in the pathogenesis of mucosal
ulcerations associated with IBD [13-15]. Furthermore,
evidence suggests that MMPs are upregulated upon
infection with pathogenic mycobacteria and MAP
thereby leading to the inflammatory tissue changes asso-
ciated with mycobacterial infections [16-18].
Within the present study we determined the preva-
lence of MAP DNA in biopsy samples of patients with
UC and CD as well as in patients without IBD using
highly sensitive and MAP specific PCRs. To analyse
a potential regulation of MMP expression by MAP
in vivo, we further assessed the colonic expression of a
broad MMP spectrum in UC patients with and without
intestinal MAP DNA detection.
Methods
Patients and biopsy samples
From June 2007 to July 2008, biopsy samples were
obtained from 63 German (n = 21) and Norwegian (n =
42) patients with IBD and from 21 German non-IBD
patients during diagnostic colonoscopies. Diagnosis of
IBD was confirmed clinically and histologically. Biopsies
were taken from areas that macroscopically showed the
highest degree of inflammation and were in closest
proximity to those biopsies taken for histopathological
examinations. Additionally samples were taken in areas
with milder signs of inflammation or normally (i.e. unaf-
fected) appearing mucosa. The Mayo endoscopic sub-
score was utilized for the macroscopic classification of
the degree of inflammation [19].
Biopsy samples from the German IBD patients (n = 21)
and the German non-IBD controls (n = 21) for MAP
culture were placed in a 1.5-ml sterile screw-cap reaction
tube containing 0.5 ml of sterile 0.85% saline and imme-
diately transferred to the laboratory for further
investigations. Samples for cultural investigation were
not frozen at any time. All biopsies scheduled for MMP
analysis were immediately cryopreserved in liquid nitro-
gen and stored at -80°C until examination. Biopsies
underwent a thorough histopathological examination and
were classified as “no”, “low-grade”, or “high-grade”
intestinal neoplasia. These examinations were carried out
by an experienced pathologist who was neither involved
in the study protocol nor aware of the particular MMP
measurements. All patients were informed about the
study and gave their written consent. In Norway the
study was approved by the ethics committee, the data
protection commissioner, and the representative
for patients’ interests and safety (Pasientvernombudet) of
the University Bergen. The Norwegian health authority
(Helsedirektorat) authorised both, the study and the ship-
ping of the tissue samples from Stavanger, Norway, to
Giessen, Germany. In Giessen the study was approved by
the local ethic committee (No 75/2009).
Culture of biopsy specimens for MAP detection
The biopsy specimens from 21 German patients with IBD
and 21 non-IBD patients was decontaminated when fresh
and subsequently cultured in separate MGIT culture tubes
at 37°C for up to 18 months. Briefly, 0.5 ml of NaOH-N-
acetyl-L-cysteine (Merck, Darmstadt, Germany) was added
to each sample in 0.5 ml of saline, and the mixture was
incubated at room temperature for 20 min with occasional
mixing by inversion. The samples were then centrifuged
(10,000 × g for 10 min), and the supernatant was removed.
The pellet was resuspended in 0.5 ml of PBS (14.6 mM
KH2PO4, 2 mM Na2HPO4 [pH 6.8]) and transferred to
the tube containing 4.5 ml of MGIT medium (Becton
Dickinson, Heidelberg, Germany) supplemented with 10%
oleic acid-albumin-dextrose-catalase (OADC), PANTA
(40 U of polymyxin B per ml, 4 μg of amphotericin B per
ml, 16 μg of nalidixic acid per ml, 4 μg of trimethoprim
per ml, 4 μg of azlocillin per ml [final concentrations]),
and 2 μg of mycobactin J (Allied Monitor, Fayette, MO,
USA) per ml. After incubation at 37°C for 12 and 52
weeks, the cultures were mixed and 0.5 ml was taken asep-
tically for testing by the MAP specific PCR as described
below. MGIT cultures with visible growth or with a posi-
tive PCR result were subcultured onto Herrold’s Egg Yolk
Medium with ANV (Ampothericin B, Nalidixic acid,
Vancomycin) and Mycobactin J and incubated at 37°C for
up to 12 months. Biopsy samples from Norwegian patients
(n = 42) were processed for direct specific PCR testing.
DNA extraction and PCR analysis for MAP detection
The DNA of the biopsy samples and MGIT cultures
after 12 and 52 weeks was extracted using a modified
protocol of the DNeasy Blood and Tissue Kit (Qiagen,
Hilden, Germany) for the extraction of DNA from
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Gram-positive bacteria. As a modification to the proto-
col of the DNeasy Blood and Tissue kit, samples were
processed in a spin/rotation instrument for cell lysis
(FastPrep-120), with a speed and time setting of 6 and
45 seconds, respectively.
For the molecular detection of MAP, two PCR systems
were set up in parallel, a triplex real time-PCR targeting
MAP specific genes F57 and ISMav2 and an internal
amplification control (IAC) [20], and a nested PCR [21]
with IS900 oligonucleotide primers. The PCR reaction
mixture for the nested PCR (50 μl) contained 1 μl pri-
mer 1 (10 pmol/μl), 1 μl primer 2 (10 pmol/μl), 1 μl
dNTP (10 mmol, Roche), 5 μl 10 × thermophilic-buffer
(Applied Biosystems, Darmstadt, Germany), 0.5 μl
MgCl2 (25 mM, Applied Biosystems), 0.5 μl Ampli Taq
Gold DNA polymerase (5 U/μl, Applied Biosystems) and
36 μl double-distilled water. Finally, 5 μl of the DNA
preparation was added to each reaction tube. The triplex
real time-PCR assay was performed as previously
described [20]. The fluorescent data were generated by
TaqMan®mgb probes applied on the ABI Prism
® 7000
Sequence Detection System according to the instruc-
tions of the supplier. Briefly, the 50 μl PCR mixture for
the triplex real time-PCR assay consisted of 25 μl of the
2xqPCR MasterMix Plus w/o uracil N-glycosylase
(UNG, Eurogentec, Seraing, Belgium), 1 μl of each pri-
mer (F57, ISMav2), 2 μl of each of the fluorogenic
probes (F57, ISMav2, IAC), 1.5 μl of the IAC, 8.5 μl of
double-distilled water and a 5-μl aliquot of the DNA
sample. The PCRs were performed in a 96well plate for-
mat on the ABI Prism® 7000 Sequence Detection Sys-
tem (Applied Biosystems). Thermal cycling conditions
comprised a Hot Start DNA Polymerase activation at
95°C for 10 minutes, 50 cycles of denaturation at 95°C
for 15 seconds, and an annealing and extension at 60°C
for 1 minute. Each measurement was performed in
duplicate, and the threshold cycle (Ct) was determined.
Primer sequences and fluorogenic probes for MAP
detection are presented in Table 1.
RNA Purification, cDNA Synthesis and RT-PCR for MMP
analyses
Biopsy samples were homogenized with a polytron
homogenizer (Kinematica, Luzern, Switzerland) and
total cellular RNA was extracted from shock-frozen sin-
gle biopsies with RNeasy Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. First-
strand cDNA was synthesized from 1 μg DNA-free total
RNA using the oligo-dT-primers and the first-strand
cDNA synthesis kit for RT-PCR (Roche Diagnostics,
Mannheim, Germany). Real time-PCR was performed
using Platinum SYBR Green qPCR Kit (Invitrogen,
Karlsruhe, Germany) according to the manufacturer’s
protocol. Real time-PCR of each gene-specific primer
pair was optimized prior to the experiment to confirm
the absence of any non-specific amplification product.
Primers were purchased from Eurofins (Ebersberg,
Germany) and primer sequences are presented in Table 2.
qRT-PCR was performed on the Mx3000P (Strata-
gene, La Jolla, USA) by using 3-stage program para-
meters as follows: 1) 10 minutes at 96°C, 2) 40 cycles of
10 seconds at 95°C, 30 seconds at 57°C, and 30 seconds
at 73°C, 3) 10 minutes at 73°C. The specificity of the
PCR was confirmed by examination of the dissociation
reaction plot subsequent to qRT-PCR. PCR products
were separated on a 1.5% TAE agarose gel and visua-
lized by staining with ethidium bromide to confirm the
appearance of a single band of the correct molecular
size. Furthermore, specificity of the PCR reactions and
the utilized primers for MMP analyses was verified in
sequencing analyses. qRT-PCR data were analysed using
the ΔΔCt model [22].
Statistical analysis
Prior to more sophisticated statistical calculations, nor-
mal distribution of the data was tested using the Kolmo-
gorov-Smirnov test and visualization of histograms.
Failing to meet criteria for normal distribution all data
were analysed using non-parametric tests. To compare
MAP DNA positive detection rates in the three groups
Table 1 Oligonucleotide primers and fluorogenic probes
for MAP detection
Designation Sequence Reference
F57 forward 5’-FTA CGA GCA CGC
AGG CAT TC-3’
Schönbrücher
et al. [20]
F57 reverse 5’-CGG TCC AGT TCG
CTG TCA T-3’
F57 TaqMan®mgb-probe VIC -CCTGACCACCC
TTC-MGB
F57 TaqMan®mgb-IAC NED-CGAGTTACA
TGATCCC-MGB
ISMav2 forward 5’-CGG CAA AAT CGA
GCA GTT TC-3’
ISMav2-R reverse 5’-TGA GCC GGT GTG
ATC ATC TTT-3’
ISMav2 TaqMan®mgb-probe FAM-CGC TGA GTT
CCT TAG-MGB
TJ1 forward 5’-GCT GAT CGC CTT
GCT CAT-3’
Bull et al. [21]
TJ2 reverse 5’-CGG GAG TTT GGT
AGC CAG TA-3’
TJ3 forward 5’-CAG CGG CTG CTT
TAT ATT CC-3’
TJ4 reverse 5’-GGC ACG GCT CTT
GTT GTA GT-3’
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CD, UC, and control patients, Fisher’s exact test was
applied. Individual MMP expression in UC affected
colonic mucosa was referred to the respective expression
in corresponding healthy mucosa of the same individual
in order to account for interindividual differences in
colonic MMP expression. Results of MMP expression
in relation to the MAP infection status are presented
in box-and-whisker-plots. The upper hinge of the box
represents the 75th percentile; the lower hinge repre-
sents the 25th percentile. The line in the box indicates
the median value of the data. The ends of the vertical
lines represent the minimum and maximum. Outliers
(□) have a distance from 1.5 to 3 box lengths from the
upper or lower hinge. Extreme values (Δ) have a dis-
tance of >3 box lengths from the upper or lower hinge.
Interindividual comparisons of MMP expression were
made using Mann-Whitney-U test. A two-sided P <
0.05 was considered significant. Statistical analysis was
performed with SPSS 17.0 (SPSS Inc, Chicago, Ill).
Results
Demographic and clinical data of the patient cohort
Intestinal biopsies were obtained during routine
colonoscopies from adult patients with CD (n = 14), UC
(n = 49) and controls without IBD or other inflammatory
disorders within the intestines (n = 21). Diagnosis of CD
and UC was confirmed in accordance with the current
guidelines based on histopathological examination and
clinical findings. Table 3 summarizes the clinical data of
these patients.
Detection of MAP in IBD patients and controls
None of the MGIT samples were positive for MAP in the
cultural investigation after 12 and 52 weeks of culture.
A total of 63 IBD patients and 21 controls were
analysed for the presence of MAP specific DNA in
Table 2 SYBR Green Real-time qPCR Primer sequences
Gene Primer Sequence GenBank
AccessionNo.
human MMP-1 Fw: 5’-AAG TTG AAA AGC GGA
GAA ATA G-3’
Rev: 5’-TTT CAA TCC TGT AGG
TCA GAT G-3’
NM 002421
human MMP-2 Fw: 5’-GGC AGA CAT CAT GAT
CAA CT-3’
Rev: 5’ TGC TGT CAT AGG ATG
TG-3’
NG 008989
human MMP-7 Fw: 5’-AGT TTA GAA GCC AAA
CTC AAG G-3’
Rev: 5’-GCG GTA AGT CTC GAG
TAT ATG-3’
NM 002423
human MMP-9 Fw: 5’-TTG ACA GCG ACA AGA
AGT GG-3’
Rev: 5’-GTA CAT AGG GTA CAT
GAG CG-3’
NG 011468
human MMP-13 Fw: 5’-GCA GTC TTT CTT CGG
CTT AG-3’
Rev: 5’-GGA GTT ACA TCG GAC
CAA AC-3’
NM 002427
human MMP-19 Fw: 5’-CTT TCA AGG GGG ACT
ATG TG-3’
Rev: 5’-TAT TCA GCT TCT TGG
GGA AG-3’
NM 002429
human MMP-28 Fw: 5’-GAG GCA TTC CTA GAG
AAG TAC G-3’
Rev: 5’-CTA GCA AAC AAG TCA
CTG ATC C-3’
NM 024302
human TNF-a Fw: 5’-CAT GTT GTA GCA AAC
CCT CA-3’
Rev: 5’-CTT GGT CTG GTA GGA
GAC G-3’
NM 000594
human 18sRNA Fw: 5’-GAT CAG ATA CCG TCG
TAG TTC C-3’
Rev: 5’-TAT CAA TCT GTC AAT
CCT GTC C-3’
NR 003286
Table 3 Demographical and clinical data of the IBD
patient cohort
UC (n = 49) CD (n = 14)
Age (years)
- mean +/-SD 39.6 +/- 13.5 32.4 +/- 13.1
- range 19-74 20-68
Sex [male/female (n)] 26/23 7/7
Disease manifestation UC (n)
- rectum 4
- rectosigmoid 19
- including C. descendens (leftsided colitis) 9
- pancolitis 17
Disease manifestation CD (n)
- terminal ileum 2
- terminal ileum + colon 6
- colon only 6
Endoscopic classification1 (n)
- mild inflammation 15 4
- moderate inflammation 27 8
- severe inflammation 7 2
Histopathologic examination (n)
- mild disease activity 20 1
- moderate disease activity 23 8
- severe disease activity 6 1
Anti-inflammatory therapy [AIT, (n)]2
- no AIT 14 1
- AIT 35 13
substance class
- 5-ASA 31 6
- corticosteroids 8 8
- immunomodulators 3 3
1Macroscopic classification of the degree of inflammation was adjusted
according to the Mayo endoscopic subscore [19].
2Some patients received different substance classes, therefore the summation
of patients in the category “substance class” exceeds the number of patients
in the category “AIT”. 5-ASA: 5-amino salicylic acid and its derivatives,
immunomodulators: azathioprine and infliximab.
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colonic mucosa. To exclude locoregional differences in
MAP infection, IBD patients from Germany (n = 21)
and Norway (n = 42) were recruited. Despite a more
frequent detection of MAP DNA in UC patients (20%)
and controls (33%) compared to patients with CD (7%)
in the total patient cohort, differences in MAP fre-
quency between these three groups were not statistically
significant (CD vs. controls: p = 0.1078, UC vs. controls:
p = 0.3615, CD vs. UC: p = 0.4298).
Subgroup analyses considering the German and
Norwegian patient cohort separately revealed likewise no
significant differences in MAP frequency between patients
with CD and UC and controls (Norway: CD vs. controls:
p = 0.2945; UC vs. controls: p = 0.1885; CD vs. UC: p =
1.00 and Germany: CD vs. controls: 0.2216; UC vs. con-
trols: p = 1.00; CD vs. UC: 0.3108). Although the MAP
detection rate was generally higher in Germany (29%)
than in Norway (14%), these differences did not reach the
level of statistical significance (p = 0.1828). MAP preva-
lence in the different cohorts is summarized in Table 4.
We next compared whether the frequency of MAP
detection in the IBD and UC patient cohort differed
depending on the applied anti-inflammatory therapy
(AIT). Comparing IBD and UC patients receiving any
kind of AIT to those patients without AIT, no statisti-
cal significances in MAP frequency were detected
(Figure 1, 2). Similarly, no significant differences in
MAP DNA prevalence were observed when patients
treated with 5-amino salicylic acid (5-ASA) and its
derivatives or immunomodulators (azathioprine and
infliximab) were compared to those patients without
the respective agents. When comparing patients strati-
fied to the treatment with corticosteroids, MAP DNA
was significantly more frequently obtained in UC
patients treated with corticosteroids compared to those
without corticosteroids in their therapeutic regime (p =
0.043, Figure 2c). However, although not statistically
significant, a higher frequency of MAP detection in the
corticosteroid group was observed in the total IBD
population as well (Figure 1c).
MMP expression in UC patients with and without
presence of MAP DNA
For MMP analyses, all determined mRNA values were
related to the respective content of 18S rRNA which
served as a housekeeping gene. In order to account for
interindividual differences in the MMP expression in the
colon, MMP expression in diseased colonic mucosa was
referred to the respective expression in corresponding
healthy mucosa of the same individual.
Gene expression of MMP-1, MMP-2, MMP-7, MMP-
9, MMP-13 and MMP-19 was unchanged between UC
patients with presence of MAP DNA and those without
(Figures 3, 4, 5, 6, 7, 8). Mucosal mRNA expression of
MMP-28 and TNF-a did not show any dependency on
the presence of MAP DNA either (Figures 9 and 10).
As MAP DNA was detected in only one CD patient,
we were unable to analyse MMP expression with regard
to MAP status in the CD patient cohort. Since endo-
scopic evaluation of screening colonoscopy did not
reveal any signs of intestinal inflammation, MMP regu-
lation in inflamed mucosa expressed as a multiple of
basal expression in healthy mucosa could not be per-
formed in the control cohort either.
Effects of anti-inflammatory agents on MMP and TNF-a
expression
To analyse a potential effect of the applied anti-inflam-
matory therapy on intestinal MMP expression, we
further calculated MMP and TNF-a expression in UC
patients stratified by the different therapeutic modalities.
Gene expression of MMP-1, -2, -7, -9, -13, -19, -28 and
TNF-a was unchanged between patients with and with-
out AIT, between patients stratified to 5-ASA and its
derivatives and between patients with and without
immunomodulators. However, median levels of MMP-2,
MMP-9, and MMP-13 were significantly decreased in
UC patients treated with corticosteroids compared to
those with no corticosteroids in their therapeutic regime
(MMP-2: 6.1-fold, p = 0.024; MMP-9: 4.2-fold,
p = 0.009; MMP-13: 9.5-fold, p = 0.042, Figures 3, 4, 5,
6, 7, 8, 9, 10).
Based on this finding, we excluded steroid-treated
patients in a further analysis and re-calculated the
MMP and TNF-a expression in MAP positive and
MAP negative IBD patients. However, despite the non-
consideration of steroid treated patients, expression of
MMP-1, -2, -7, -9, -13, -19, -28 and TNF-a remained
unchanged between MAP positive and negative IBD
patients (Additional Files 1, 2, 3, 4).
Table 4 Frequency MAP DNA detection in IBD patients
and controls
Patient cohort (n) MAP
positive (n)
MAP
negative (n)
Control cohort (n = 21) 7 (33%) 14 (67%)
IBD patients Germany
-CD (n = 10) 1 (10%) 9 (90%)
-UC (11) 4 (36%) 7 (64%)
IBD patients Norway
-CD (n = 4) 0 (0%) 4 (100%)
-UC (n = 38) 6 (16%) 32 (84)
IBD patients Norway + Germany
-CD (n = 14) 1 (7%) 13 (93%)
-UC (n = 49) 10 (20%) 39 (80%)
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Figure 1 Frequency of intestinal MAP DNA detection in subgroups of IBD patients (n = 63). Comparisons were made using Fisher’s exact
test. For visualization, the number of patients in each subgroup was converted to 100% and the percentage of MAP positive and negative
patients in each subgroup is shown, respectively. Frequency of MAP specific DNA was not altered between IBD patients with anti-inflammatory
therapy (AIT) and those without (A). Similarly, there were no differences in MAP frequency between IBD patients treated with 5-amino salicylic
acid (5-ASA) and its derivatives (B) or immunomodulators (azathioprine and infliximab, D) and those without the respective agents. Although not
statistically significant, MAP DNA was more frequently found in IBD patients treated with corticosteroids compared to those without (C).
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Figure 2 Frequency of intestinal MAP DNA detection in subgroups of UC patients (n = 49). Comparisons were made using Fisher’s exact
test. For visualization, the number of patients in each subgroup was converted to 100% and the percentage of MAP positive and negative patients
in each subgroup is shown, respectively. UC patients treated with corticosteroids had a significantly higher frequency of MAP detection than UC
patients receiving no corticosteroids (C) whereas the detection of MAP DNA was not altered between IBD patients with anti-inflammatory therapy
(AIT) and those without (A). Frequency of MAP specific DNA was not changed between UC patients treated with 5-amino salicylic acid (5-ASA) and
its derivatives (B) or immunomodulators (azathioprine and infliximab, D) compared to those without the respective agents.
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Figure 3 Expression of MMP-1 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-1 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.694) and did not differ between patients receiving
an anti-inflammatory therapy (AIT) and those without AIT (p = 0.973). Further stratification into subgroups of patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives, corticosteroids or immunomodulators (azathioprine and infliximab) revealed no significant differences in MMP-1
expression between patients treated with the respective substance and those not receiving the respective agent. Note, that some patients
received more than one substance class and therefore appear in more than one subgroup.
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Figure 4 Expression of MMP-2 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-2 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.780) and did not differ between patients receiving an
anti-inflammatory therapy (AIT) and those without AIT (p = 0.449). Further stratification of the UC cohort according to the different therapeutic
agents revealed that MMP-2 mRNA is significantly decreased by factor 6.1 in UC patients treated with corticosteroids compared to those with no
corticosteroids in their therapeutic regime (p = 0.024). No differences in MMP-2 expression were observed when patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives or immunomodulators (azathioprine and infliximab) were compared to patients not treated with the respective
agent. Note, that some patients received more than one substance class and therefore appear in more than one subgroup.
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Figure 5 Expression of MMP-7 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-7 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.318) and did not differ between patients receiving
an anti-inflammatory therapy (AIT) and those without AIT (p = 0.094). Further stratification into subgroups of patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives, corticosteroids or immunomodulators (azathioprine and infliximab) revealed no significant differences in MMP-7
expression between patients treated with the respective substance and those not receiving the respective agent. Note, that some patients
received more than one substance class and therefore appear in more than one subgroup.
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Figure 6 Expression of MMP-9 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-9 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.243) and did not differ between patients receiving an
anti-inflammatory therapy (AIT) and those without AIT (p = 0.561). Further stratification of the UC cohort according to the different therapeutic
agents revealed that MMP-9 mRNA is significantly decreased by factor 4.2 in UC patients treated with corticosteroids compared to those with no
corticosteroids in their therapeutic regime (p = 0.009). No differences in MMP-9 expression were observed when patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives or immunomodulators (azathioprine and infliximab) were compared to patients not treated with the respective
agent. Note, that some patients received more than one substance class and therefore appear in more than one subgroup.
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Figure 7 Expression of MMP-13 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-13 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.552) and did not differ between patients receiving an
anti-inflammatory therapy (AIT) and those without AIT (p = 0.348). Further stratification of the UC cohort according to the different therapeutic
agents revealed that MMP-13 mRNA is significantly decreased by factor 9.5 in UC patients treated with corticosteroids compared to those with no
corticosteroids in their therapeutic regime (p = 0.042). No differences in MMP-13 expression were observed when patients receiving 5-amino
salicylic acid (5-ASA) and its derivatives or immunomodulators (azathioprine and infliximab) were compared to patients not treated with the
respective agent. Note, that some patients received more than one substance class and therefore appear in more than one subgroup.
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Figure 8 Expression of MMP-19 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-19 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.678) and did not differ between patients receiving
an anti-inflammatory therapy (AIT) and those without AIT (p = 0.110). Further stratification into subgroups of patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives, corticosteroids or immunomodulators (azathioprine and infliximab) revealed no significant differences in MMP-19
expression between patients treated with the respective substance and those not receiving the respective agent. Note, that some patients
received more than one substance class and therefore appear in more than one subgroup.
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Figure 9 Expression of MMP-28 in UC patients (n = 49). mRNA results were determined by RT-PCR. MMP-28 gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.370) and did not differ between patients receiving
an anti-inflammatory therapy (AIT) and those without AIT (p = 0.602). Further stratification into subgroups of patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives, corticosteroids or immunomodulators (azathioprine and infliximab) revealed no significant differences in MMP-28
expression between patients treated with the respective substance and those not receiving the respective agent. Note, that some patients
received more than one substance class and therefore appear in more than one subgroup.
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Discussion
The histopathological and clinical similarities between
human chronic granulomatous enteritis, intestinal tuber-
culosis, and animal paratuberculosis [3,23] has led to
the suspicion that Mycobacterium avium subspecies
paratuberculosis is an etiologic factor for the develop-
ment of Crohn’s disease. MAP is fastidious and slow-
growing and can therefore only rarely be detected by
conventional microbiological techniques [1]. Due to the
difficulties in growing MAP in vitro, molecular and ser-
ological methods have been developed. Nevertheless, the
molecular detection of MAP DNA has also frequently
been hampered by insufficient specificity of the selected
primers and probes, inadequate DNA extraction meth-
ods resulting in insufficient sensitivity, and possible con-
tamination as a consequence of the PCR techniques
used [24]. In the current study, we therefore selected a
nested PCR system and a real time-PCR method instead
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Figure 10 Expression of TNF-a in UC patients (n = 49). mRNA results were determined by RT-PCR. TNF-a gene expression was not
significantly different in UC patients with intestinal MAP detection and those without (p = 0.416) and did not differ between patients receiving
an anti-inflammatory therapy (AIT) and those without AIT (p = 0.533). Further stratification into subgroups of patients receiving 5-amino salicylic
acid (5-ASA) and its derivatives, corticosteroids or immunomodulators (azathioprine and infliximab) revealed no significant differences in TNF-a
expression between patients treated with the respective substance and those not receiving the respective agent. Note, that some patients
received more than one substance class and therefore appear in more than one subgroup.
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of conventional PCR sets, which ensured a sensitive and
specific approach. The nested PCR used was developed
by Bull et al. [21] and is based on the widely used MAP
reference marker IS900. The oligonucleotide primer
sequences were specifically adapted to show no cross
reactions with the previously described IS900-like ele-
ments [25,26]. The positive IS900 PCR products
detected were sequenced and corresponded to MAP
IS900 but not IS900-like sequences. In addition, a tri-
plex real-time PCR assay combining the MAP-specific
gene sequences F57, ISMav2, and an internal amplifica-
tion control for diagnostic quality assurance was applied.
The real time-PCR method was carefully validated by
using more than 200 references and field strains with
different kinds of sample preparation techniques on arti-
ficially contaminated and naturally infected samples.
Based on 2 different PCR methods utilized in this
study, false-positive results due to an unspecific binding
of oligonucleotide primer pairs are therefore highly
improbable. The risk of cross-contamination between
the samples was also reduced by using sample prepara-
tion negative controls. The use of an IAC has been
shown to be mandatory for diagnostic PCR applications
to exclude false negative results [27]. The included IAC
of the real-time PCR assay revealed that none of the
real-time PCR reactions was inhibited.
Using this specific and sensitive approach, we explored
the detection rate of MAP DNA in colonic biopsies of
German and Norwegian patients with IBD and control
patients without intestinal inflammation. Within this
study, we found no significant differences in MAP DNA
detection frequency between patients with UC and CD
and controls.
Regarding the literature, reports about the associa-
tion of MAP and CD are controversial. So far, a num-
ber of studies have reported more frequent detection
of MAP DNA in CD patients compared with controls
using PCR assays [21,28,29]. Other authors, in con-
trast, found no association between CD and the detec-
tion of MAP DNA [30-35]. Nevertheless, comparisons
between the studies are difficult to make due to het-
erogeneity in the analysed specimens that vary from
fresh [35,36] to embedded tissue [30,31] and blood
[28,29,32-34]. Furthermore, different MAP detection
methods are used across the studies including MAP
DNA [21,28,30,31,33-35], MAP culture [29,32,34],
both DNA and culture [34], specific antibodies against
MAP epitopes [28] and immunocytochemistry [31].
Although recent meta-analyses were able to confirm
the association of MAP infection and CD [4,6], the
pathogenic significance of this association remains
unclear. Within our study, we detected MAP DNA in
only a low percentage of CD patients. As a limiting
factor, our cohort of patients with CD was relatively
small. Post hoc power analysis of the CD population
against an alpha level of 0.05 estimated a two-tailed
statistical power of 0.135. Consequently, appropriate
conclusions about an etiologic involvement of MAP in
the pathogenesis of CD cannot be drawn from the
results of our study.
During the initial phase of our study, we detected MAP
DNA in an unexpected high percentage of German UC
patients. To exclude a locoregional influence or epiphe-
nomenon, we aimed to confirm this result in a distinct
UC population and therefore expanded our analyses to a
cohort of Norwegian UC patients. In this cohort, we like-
wise observed a high frequency of MAP DNA. Data on
the frequency of MAP detection in UC in the literature
are contradictory as well. In general, MAP is more
frequently detected in CD than in UC according to recent
meta-analyses [4,6]. Nevertheless, several studies detected
MAP infection in a high percentage of UC patients as
well [7,28,37-40].
As a further remarkable result, we detected MAP
DNA in intact colonic mucosa in a high percentage of
German control patients (33%). As both, the Norwegian
and German patient population represent an urban
population with a comparable demographic and epide-
miologic structure and a similar BCG vaccination policy
in Germany and Norway, we did not assess the colonic
MAP prevalence in healthy Norwegians. In conjunction
with our results, previous studies have made similar
observations by serologically detecting MAP DNA or
specific MAP antibodies in a high percentage of healthy
control patients [37,39-41]. In this context, the following
aspects are important to note: MAP has been cultured
from chlorinated potable municipal water [42]. Myco-
bacteria are at least two orders of magnitude more resis-
tant to chlorine purification than Escherichia coli and
MAP survives higher concentrations of chlorine than
the 1.1 parts per million routinely achieved with first-
use municipal water in the USA [43]. Furthermore,
MAP has been cultured from pasteurized milk in the
USA and Europe [44-46]. Considering these facts, it has
been speculated that the frequent detection of MAP in
healthy controls is a result of the wide distribution of
MAP and its presence in the food-chain. Nevertheless,
the biological significance of this finding remains
unclear as the detection of MAP DNA might well come
from live bacteria but also might merely represent scat-
tered debris from killed bacteria.
Anti-inflammatory agents such as 5-ASA and its deri-
vatives, corticosteroids and immunomodulators are
established therapeutic agents for the treatment of IBD.
Most interestingly, it has been shown that 5-ASA, thali-
domide, methotrexate, 6-mercaptopurine and azathiopr-
ine inhibit MAP in vitro in a dose dependent manner
[47-50]. Further, recent evidence suggests that 5-ASA
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decreases the prevalence of MAP DNA from the blood
of IBD patients whereas other agents such as 6-mercap-
topurin, methotrexate and tacrolimus are associated
with clearance of MAP DNA from the blood [39]. To
analyse a potential effect of the applied anti-inflamma-
tory therapy on the MAP DNA prevalence in intestinal
tissue, we performed subgroup analyses according to the
different therapeutic agents in our IBD cohort. However,
we were not able to detect significant differences in the
MAP DNA prevalence between IBD and UC patients
with and without anti-inflammatory therapy and
between those patients receiving 5-ASA or immunomo-
dulators compared to patients without the respective
agents. Based on the unrefuted data of the anti-MAP
activities of IBD medication mentioned above, we
assume that the most likely explanation for the lack of
association between 5-ASA and immunomodulators and
MAP detection rates within our study, apart from the
different specimens analysed (tissue vs. blood), is the
relative small sample size in our study. Nevertheless, our
results provide evidence that UC patients treated with
corticosteroids have a higher frequency of intestinal
MAP DNA than those not treated with corticosteroids.
This result is in accordance with observations from
Naser et al. who cultured MAP from blood in 60% (3 of
5) of IBD patients treated with steroids [29]. Although a
larger study by Juste and co-workers did not detect a
significant increase in MAP prevalence in patients
receiving steroids, the authors suggested that the lack of
increased MAP DNA frequency in steroid treated IBD
patients in their study might be attributable to frequent
co-administration of anti-MAP agents in this group
[39]. Furthermore, the authors concluded that caution
suggests that concomitant anti-MAP agents should
always be used when steroids are administered [39], a
position that is strengthened by the results of our study.
To further evaluate a potential contribution of MAP
infection to disease manifestation in UC patients, we
analysed the expression of Matrix Metalloproteinases
with regard to the presence or absence of intestinal
MAP DNA. Members of the MMP family have been
shown to be upregulated in peripheral blood mononuc-
lear cells from cattle infected with Johne’s disease after
stimulation with MAP [16,17]. Furthermore, murine
in vitro and in vivo studies provide evidence that upre-
gulation of certain MMPs such as MMP-2 and MMP-9
plays a pathogenic role in infections caused by patho-
genic mycobacteria [18]. Most interestingly, enhanced
MMP activity after mycobacterial infection was substan-
tially reduced upon treatment with anti-TNFa antibo-
dies [18], a treatment strategy which has been proven to
be highly beneficial in human IBD [51,52]. On the other
hand, in vitro data from Janagama and co-workers
demonstrate that MAP strains from diverse hosts differ
in their ability to survive intracellularly and that strains
with higher intracellular persistence had decreased
expression of different cytokines and MMP-3 [53].
Thus, an anti-inflammatory and anti-invasive milieu
might facilitate their persistence and survival within
macrophages [53].
On the basis of this evidence, we aimed to analyse the
mucosal MMP expression in IBD patients with and with-
out intestinal MAP DNA. Unfortunately, we had to
restrict the analysis to the UC patient cohort, as MAP
DNA was detected in only one CD patient. Using this
approach we focused on MMP gene expression as several
studies have shown that expression of MMPs is mainly
transcriptional regulated with close correlation between
MMP protein concentrations and mRNA expression
[54-57]. We analysed a broad spectrum of MMPs includ-
ing MMP-1, MMP-7 and MMP-13, which have been pro-
ven to be major proteases in the pathogenesis of IBD
associated mucosal ulcerations [13-15,58,59], and MMP-2
and MMP-9, which have been shown to be upregulated
upon mycobacterial infection [18]. Furthermore, we deter-
mined the expression of MMP-28, the most recent mem-
ber of the MMP family which is expressed in intact
colonic epithelium rather than in UC affected mucosa and
therefore is associated with epithelial integrity [14,60]. Our
results provide evidence that neither expression of MMP-
1, -2, -7, -9, -13, -19 nor of MMP-28 is altered in UC
patients with presence of intestinal MAP DNA compared
to those without MAP detection. TNF-a, which regulates
MMP-2 and MMP-9 and is part of the cytokine response
towards MAP in CD patients [10,11,61,62], was
unchanged between UC patients with intestinal MAP
DNA detection and those without. Subgroup analyses
based on different anti-inflammatory agents applied in our
IBD cohort revealed significantly decreased MMP-2,
MMP-9, and MMP-13 gene transcripts in UC patients
treated with corticosteroids compared to those with
no corticosteroids in their therapeutic regime (MMP-2:
6.1-fold, p = 0.024; MMP-9: 4.2-fold, p = 0.009; MMP-13:
9.5-fold, p = 0.042). However, when we excluded steroid-
treated patients in a further analysis and re-calculated the
MMP and TNF-a expression in MAP positive and MAP
negative IBD patients, no significant differences were
observed between MAP positive and MAP negative
patients (Additional Files 1, 2, 3, 4).
To further elucidate the pathogenic potential of MAP
for the development of IBD and its significance in healthy
individuals, it seems inevitable to transfer the results of
the observed association of MAP and IBD to more func-
tional studies in the future. To understand different sus-
ceptibilities towards MAP infections, it will be of great
value to determine the presence or absence of certain
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genetic IBD risk loci in CD and UC patients. Among
others, NOD2 and Nramp1 might be of particular inter-
est in the context of MAP infection: approximately 30%
of European ancestry have one of three NOD2 poly-
morphisms and homozygosity for one polymorphism
confers an increased risk for CD by factor 11 to 27 [2].
Interestingly, embryonic kidney cells transfected with
NOD2 are able to recognize MAP and respond in a dose
dependent manner [63]. Defects and mutations in Nrmap
(natural-resistance-associated macrophage protein 1) are
associated with increased susceptibility to mycobacterial
infections in humans and animals and in both, UC and
CD patients have a frequency of Nramp1 promoter poly-
morphisms than healthy controls [64]. Another potential
approach might be the use murine models with knock-
down of certain IBD susceptibility loci and subsequent
controlled infection with MAP strains and other
mycobacteria.
Conclusions
Our study provides evidence that MAP can frequently
be detected in intestinal mucosa of patients suffering
from ulcerative colitis as well as from control patients
without intestinal inflammation. This result might well
be attributable to the wide environmental distribution of
MAP and its presence in the food-chain. Furthermore,
we are able to show that corticosteroids are associated
with increased detection of intestinal MAP DNA and
decreased expression of certain MMPs. The results of
this study provide further evidence that the presence of
intestinal MAP specific DNA is not associated with
altered MMP expression in ulcerative colitis in vivo.
Hence, the biological significance of MAP and its contri-
bution to the pathogenesis of IBD remains elusive.
Additional material
Additional file 1: Expression of MMP-1 and MMP-2 in UC patients
without corticosteroids with respect to the presence of MAP DNA
(n = 41). mRNA results were determined by RT-PCR. MMP-1 and MMP-2
gene expression was not significantly different in steroidfree UC patients
with intestinal MAP detection compared to those without.
Additional file 2: Expression of MMP-7 and MMP-9 in UC patients
without corticosteroids with respect to the presence of MAP DNA
(n = 41). mRNA results were determined by RT-PCR. MMP-7 and MMP-9
gene expression was not significantly different in steroidfree UC patients
with intestinal MAP detection compared to those without.
Additional file 3: Expression of MMP-13 and MMP-19 in UC patients
without corticosteroids with respect to the presence of MAP DNA
(n = 41). mRNA results were determined by RT-PCR. MMP-13 and MMP-
19 gene expression was not significantly different in steroidfree UC
patients with intestinal MAP detection compared to those without.
Additional file 4: Expression of MMP-28 and TNF-a in UC patients
without corticosteroids with respect to the presence of MAP DNA
(n = 41). mRNA results were determined by RT-PCR. MMP-28 and TNF-a
gene expression was not significantly different in steroidfree UC patients
with intestinal MAP detection compared to those without.
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